| 查看: 1080 | 回复: 2 | |||
| 本帖产生 1 个 翻译EPI ，点击这里进行查看 | |||
[求助]
求翻译，谢谢，站内信
|
|||
|
Actinomycetes have been prolific sources of novel secondary metabolites with a range of biologi- cal activities that may ultimately find application as therapeutic compounds. Hence several drug discovery companies are engaged in isolation of novel bioactive metabolites from these microbial sources. Antibiotics form the major class of such bioactive metabolites and have been widely used for treating infectious diseases. One of the most critical problems in clinical practice is the in- crease of prevalence of drug resistant strains, especially azole resistance among fungi. Due to this, there is a constant need for development of new antifungal antibiotics having novel scaffolds and/or mechanism of action. In our in-house screening program in the quest of novel and superior antifungal compounds, an actinomycetes strain PM0525875 was isolated from a marine inverte- brate. The extracts of this microbe showed potent in-vitro antifungal activity against drug resis- tant fungal strains. The antifungal active peak from the extract obtained by shake flask fermenta- tion was identified by chromatographic and other analytical techniques during bioactivity guided isolation. Later the fermentation conditions were optimized in 30 L fermentor for the production of sufficient amount antifungal compound for complete structural characterization. Consequently the fermented broth extract was subjected to bioactivity-guided fractionation, to isolate the active principle using different preparative chromatographic techniques followed by its characterization. The active principle was characterized to be Caerulomycin A. Minimum inhibitory concentration (MIC) of the compound was found in the range of 0.39 - 1.56 μg/ml against pathogenic fungal test strains. The phylogenetic analysis of producer strain using 16S rRNA sequence showed closest match with Actinoalloateichus cyanogriseus. Herewith we report the isolation of Caerulomycin A from marine invertebrate-associated Actinoalloteichus sp. using optimized medium and fermenta- tion conditions. |
回复此楼» 猜你喜欢
289 分105500药学专硕求调剂(找B区学校)
已经有5人回复
-
291求调剂
已经有11人回复
-
304求调剂
已经有8人回复
-
求调剂推荐
已经有9人回复
-
B区0809 ，数一英一，290 求调剂
已经有5人回复
-
求调剂
已经有12人回复
-
291求调剂
已经有13人回复
-
085404 22408 309分求调剂
已经有11人回复
-
求调剂
已经有7人回复
-
有没有接收比较快的sci期刊呀，最好在一个月之内的，研三孩子求毕业
已经有6人回复
蹉跎岁月
木虫 (正式写手)
- 翻译EPI: 40
- 应助: 77 (初中生)
- 金币: 5706.1
- 散金: 484
- 红花: 11
- 帖子: 954
- 在线: 587.1小时
- 虫号: 2021440
- 注册: 2012-09-22
- 性别: GG
- 专业: 木材科学与技术
【答案】应助回帖
★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★
bxzc123: 金币+20, 翻译EPI+1, ★★★很有帮助 2014-10-26 21:26:58
bxzc123: 金币+20, 翻译EPI+1, ★★★很有帮助 2014-10-26 21:26:58
|
有诸多生物活性可能最终应用于治疗的化合物，含有活性次生代谢物的放线菌资源丰富。因此，一些药物研发公司致力于从这些微生物的资源中分离活性次生代谢产物。 抗生素是这种活性次生代谢产物的主要成分并被广泛的用于治疗传染性疾病，在医疗实践中最主要的问题之一就是普遍增长的耐药性菌株，特别是对于菌类中唑类药物的耐药性。正因为此，对于起主导地位和作用机制的新抗真菌抗生素的研究一直都是必要的。在我们内部对于新的和优等的抗真菌的化合物的筛选项目中，从海洋无脊椎动物中分离出了放线菌菌株 PM0525875 |
2楼2014-10-26 19:51:25
蹉跎岁月
木虫 (正式写手)
- 翻译EPI: 40
- 应助: 77 (初中生)
- 金币: 5706.1
- 散金: 484
- 红花: 11
- 帖子: 954
- 在线: 587.1小时
- 虫号: 2021440
- 注册: 2012-09-22
- 性别: GG
- 专业: 木材科学与技术
【答案】应助回帖
★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★
bxzc123: 金币+35, ★★★很有帮助 2014-10-26 21:27:03
bxzc123: 金币+35, ★★★很有帮助 2014-10-26 21:27:03
| 这种细菌的抽提物表明体外抗真菌性能在抑制真菌菌株的耐药性是有效的。使用摇瓶发酵法，生物活性物的分离采用色析法和其他分析分析方法，从抽提物中获得的抗真菌峰被识别出来。然后对于足量的抗真菌化合物的生产，进行结构表征最佳的发酵条件为在30L的发酵罐中。因此，发酵液体培养基抽提物采用活性导向分馏法，根据其描述，使用不同的色谱技术去分离有效成分。活性成分中以浅蓝霉素A为主，对于抵抗致病真菌实验株，化合物最低抑菌浓度范围在0.39--1.56 μg/ml 之间。使用16S rRNA序列方法，菌株产生菌的种系进化分析表明和Actinoalloateichus cyanogriseus.最为接近。因此，我们研究出最佳媒介和发酵条件，从海洋无脊椎与Actinoalloteichus相近的属中分离出浅蓝霉素A |
3楼2014-10-26 20:40:13
50